Loading...
Prescribing of sulfonylureas, generally as add-on therapy when metformin alone does not achieve adequate glycemic control in patients with type 2 diabetes, has been decreasing in recent years (PLoS One 2019; 14:e0221174). This trend likely reflects two major developments: First, newer agents — in particular, the dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 (SGLT-2) inhibitors, and glucagon-like peptide-1 (GLP-1) receptor agonists — are marketed heavily by the pharmaceutical industry to physicians and advertised directly to consumers. And second, longstanding concern about the cardiovascular (CV) safety of sulfonylureas has gained traction. When these two factors are considered alongside the two principal adverse…